How CRISPR Is Rewriting Medicine Faster Than Regulators Can Follow
December 29, 2025 · Frisian News
Gene-editing technology CRISPR now treats blood disorders and cancers in clinics worldwide, but governments and health agencies struggle to keep pace with its speed and cost decisions.
A clinic approved CRISPR treatment for a patient with sickle cell disease. Until recently, no hospital outside experimental trials could offer this at all. Today, clinics in the United States, Europe, and Asia run CRISPR programs. The technology now works. Regulators have not yet agreed on how to price it, who pays, or what happens when it fails.
The speed of CRISPR's clinical use has outpaced every regulatory system designed to control it. The European Medicines Agency approves new drugs through a process that takes years. CRISPR therapies, by contrast, move from lab to patient in months because private clinics in countries with loose oversight run the treatments first. Rich patients fly to these clinics, pay cash, and return home. Their results then pressure governments to approve the same treatment domestically. Regulators follow, not lead.
Cost creates another gap that regulators cannot fill. Gene therapies using CRISPR carry high costs per patient depending on the disease. Health systems in wealthy countries struggle to fund even one case per year. Meanwhile, biotech firms point to the personalized nature of each therapy and claim high prices reflect real costs. No country has yet forced prices down, and no country has agreed on who should bear the cost when a therapy fails to work. This leaves ordinary people choosing between saving for a house and saving their life.
The real problem runs deeper than speed or cost. CRISPR works by cutting DNA and rewriting genetic code inside living cells. Off-target cuts can cause mutations and cancer years later. Long-term safety data does not exist because the technology is too new. Regulators in most countries require years of follow-up data before approving any drug. CRISPR therapies have perhaps two years of data at best. Patients sign consent forms acknowledging unknown risks, but governments have not decided whether this consent alone justifies wider use.
Small countries face a choice: ban CRISPR and watch citizens seek treatment abroad, or permit it and take responsibility for unknown harms. Large countries delay, hoping other nations run the experiments first. Meanwhile, researchers and clinics move forward. The technology will not wait for bureaucrats to catch up. By the time regulators agree on rules, CRISPR will have moved on to other diseases, other cell types, other complexities that nobody can yet predict.
Published December 29, 2025 · Frisian News